-
MCC950 sodium: From NLRP3 Signal to Cell Fate
2026-09-09
MCC950 sodium is a selective NLRP3 inflammasome inhibitor for connecting inflammatory signaling with pyroptotic cell injury. This article develops a phenotype-first framework for interpreting macrophage, endothelial, and autoimmune disease experiments.
-
Annexin V-FITC/PI Apoptosis Assay Kit Workflow
2026-09-08
Turn phosphatidylserine externalization and membrane damage into a practical, quantitative cell-death readout with the Annexin V-FITC/PI Apoptosis Assay Kit. This guide connects flow cytometry apoptosis detection to the multi-omics study of processed Rehmannia, while emphasizing controls, tissue-specific handling, and troubleshooting.
-
Sulfo-NHS-SS-Biotin: Surface Labeling Logic
2026-09-08
Sulfo-NHS-SS-Biotin enables selective, reversible labeling of extracellular proteins while preserving a route to affinity purification and controlled biotin removal. This guide explains how to design, interpret, and troubleshoot surface-labeling assays in light of emerging glycoRNA–RNA-binding protein biology.
-
Super-Enhancer Control of KLF6 in Adipogenesis
2026-09-07
Nguyen et al. identify a functional super-enhancer circuit that induces KLF6 during the adipogenic differentiation of human adipose-derived stem cells. Their experiments connect PPARγ/p300- and enhancer RNA-dependent activation of KLF6 with HDAC3-mediated repression of DLK1, providing a mechanistic framework for how chromatin regulation coordinates adipocyte formation.
-
AMG 487: Context-Aware CXCR3 Assay Design
2026-09-05
AMG 487 is a potent CXCR3 antagonist for dissecting chemokine signaling, migration, calcium flux, and macrophage-state effects. This guide moves beyond pathway description to explain how assay context, orthogonal readouts, and LAMP1-linked biology should shape experimental interpretation.
-
EZ Cap™ Cas9 mRNA: Causal Neurobiology
2026-09-05
EZ Cap™ Cas9 mRNA (5-moUTP) enables transient CRISPR-Cas9 genome editing for testing Fyn–Stat3 causality in zebrafish neurodegeneration models. This article focuses on assay architecture, mechanistic controls, RNA chemistry, and interpretation beyond phenotype-only gene editing studies.
-
rTMS, GABAergic Neurons, and Amyloid Clearance in AD
2026-09-04
This study identifies a mechanistic link between repetitive transcranial magnetic stimulation, GABAergic neuron activity, and microglial amyloid clearance in 5xFAD mice. Its single-cell and pathological analyses suggest that Cx3cl1–Cx3cr1 signaling may connect neuromodulation with reduced plaque burden, lower neuroinflammation, and improved cognitive performance.
-
BCS Biowaiver Evidence for Taltirelin ODTs
2026-09-04
Ono and Sugano tested whether BCS-based biowaiver principles could support bioequivalence assessment between orally disintegrating tablets and immediate-release products for BCS class III drugs. Using dissolution comparisons across six model drugs, they found that taltirelin and olopatadine satisfied the relevant dissolution criteria, while several drugs with higher dose-to-solubility ratios showed formulation-dependent profiles despite clinical bioequivalence.
-
SB 431542 in PSC Muscle Regeneration Assays
2026-09-03
SB 431542 offers a precise way to interrogate ALK5-dependent TGF-β signaling in human pluripotent stem cell muscle models. This article connects Smad2 phosphorylation inhibition with long-term graft maturation, satellite-cell formation, and more informative assay design.
-
Mecamylamine Hydrochloride in Gut-Brain Assays
2026-09-03
Mecamylamine hydrochloride gives researchers a fast pharmacological way to test whether cholinergic signaling contributes to gut-brain effects, while its nonselective activity demands careful controls. This workflow translates recent Bacteroides fragilis seizure findings into receptor, vagal, and neuropsychiatric assay decisions without treating mechanistic evidence as a therapeutic claim.
-
Dextromethorphan hydrobromide in Neuroprotection
2026-09-02
Dextromethorphan hydrobromide supports controlled studies of NMDA-driven excitotoxicity, ion-channel modulation, and neuronal survival. This practical guide combines concentration design, injury-model selection, orthogonal readouts, and troubleshooting for more reproducible neuroprotection research.
-
Hoe 140: Potent Long-Acting Bradykinin Antagonism
2026-09-02
The 1991 study introduced Hoe 140 as a highly potent bradykinin antagonist with substantially greater in vitro activity than earlier peptide antagonists. Its combination of receptor-binding, isolated-organ, and endothelial-cell assays established a strong pharmacological basis for blocking bradykinin-mediated smooth-muscle and vascular signaling, while also revealing important limits on interpreting in vitro duration and selectivity.
-
Polygodial for TRPA1 Assay Design and Signaling
2026-09-01
Polygodial provides a chemically defined way to activate TRPA1 in acute calcium-imaging assays and longer epithelial signaling workflows. Its value is greatest when researchers pair rapid ion-channel measurements with Ca²⁺/NFAT-dependent inflammatory readouts and appropriate pathway controls.
-
HyperScribe™ Poly (A) Tailing Kit Workflow
2026-08-31
Build more consistent polyadenylated RNA for transfection experiments, micro-injection, and mechanistic gene-expression studies. The workflow combines a defined E-PAP reaction with RNA quality controls that help distinguish poor transcript performance from biology, including mitochondrial OGDH regulation.
-
FXR–KLF11 Signaling in Contrast-Induced Kidney Injury
2026-08-31
The reference study identifies an FXR–KLF11 transcriptional axis that suppresses JAK2/STAT3 signaling and reduces contrast-induced acute kidney injury in mouse and HK-2 cell models. Its findings position Chenodeoxycholic Acid (CDCA) as a mechanistic probe for studying nuclear receptor control of renal inflammation and apoptosis, while highlighting the need for further validation before clinical translation.